EGFR and non-small cell lung carcinoma: Originally broadly approved for the treatment of NSCLC in 2004, erlotinib’s indications were later narrowed to first-line, maintenance, or subsequent therapy in patients with EGFR exon 19 deletions or L858R substitutions as a result of the EURTAC and IUNO studies in 2016.